Patents by Inventor Brad M. Savall

Brad M. Savall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P2X7 MODULATORS
    Publication number: 20240116930
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 11, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus ALCAZAR VACA, Jose Lgnacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS
    Publication number: 20240109901
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: June 2, 2023
    Publication date: April 4, 2024
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • P2X7 modulators
    Patent number: 11820770
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: November 21, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
    Patent number: 11667644
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: June 6, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • P2X7 MODULATORS
    Publication number: 20220213095
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 7, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus ALCAZAR VACA, Jose Ignacio ANDRES GIL, Christa C. CHROVIAN, Heather R. COATE, Meri DE ANGELIS, Curt A. DVORAK, Christine F. GELIN, Michael A. LETAVIC, Brad M. SAVALL, Akinola SOYODE-JOHNSON, Brice M. STENNE, Devin M. SWANSON
  • P2X7 modulators
    Patent number: 11225478
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 18, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators
    Publication number: 20210347781
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 11, 2021
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
    Patent number: 11059828
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: July 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • P2X7 Modulators
    Publication number: 20200325138
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • P2X7 modulators
    Patent number: 10703749
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: July 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
    Publication number: 20200048263
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 13, 2020
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • P2X7 Modulators
    Publication number: 20190092770
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 28, 2019
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Fused azaheterocyclic compounds and their use as AMPA receptor modulators
    Patent number: 10155769
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: December 18, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Terry Patrick Lebold, Suchitra Ravula, Brad M. Savall, Brock T. Shireman
  • P2X7 modulators
    Patent number: 10150765
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: December 11, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • P2X7 modulators and methods of use
    Patent number: 10112937
    Abstract: The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 30, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Brett D. Allison, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Xiaohu Deng, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Jimmy T. Liang, Neelakandha S. Mani, Jason C. Rech, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson, Jessica L. Wall
  • 3-aryl-2H-pyrazolo[4,3-b]pyridine compounds and their use as AMPA receptor modulators
    Patent number: 10100045
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 16, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Brad M. Savall, Warren Stanfield Wade, Stephen Todd Meyer, Márió Gyuris
  • Fused bicylic pyridine compounds and their use as AMPA receptor modulators
    Patent number: 10087185
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 2, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Márió Gyuris, Brian Ngo Laforteza, Terry Patrick Lebold, Stephen Todd Meyer, Suchitra Ravula, Brad M. Savall, Brock T. Shireman, Warren Stanfield Wade, János Gerencsér
  • Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
    Patent number: 10053463
    Abstract: The present invention is directed to a compound of Formula (I).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 21, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Jason C. Rech, Brad M. Savall, Jessica L. Wall
  • Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
    Patent number: 10047092
    Abstract: The present invention is directed to a compound of Formula (I) and to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: August 14, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Jason C. Rech, Brad M. Savall
  • Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
    Patent number: RE48841
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 7, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode-Johnson, Emily M. Stocking, Devin M. Swanson